Literature DB >> 6119221

A comparison of the effects of neuroleptics on phencyclidine-induced behaviors in the rat.

R D Sturgeon, R G Fessler, S F London, H Y Meltzer.   

Abstract

The dose-response effects of neuroleptic pretreatment on phencyclidine (PCP; 3 or 5 mg/kg)-induced locomotor activity, stereotyped behaviors and ataxia were quantified in groups of male rats using rating scales recently developed in this laboratory. Three butyrophenone neuroleptics consistently produced dose-dependent antagonism of the behavioral effects of PCP administration. Fluphenazine antagonized the behavioral effects produced by 3 mg/kg PCP but not those produced by 5 mg/kg PCP. Each of the other neuroleptics examined (chlorpromazine, thioridazine, mesoridazine, triflupromazine, cis-flupenthixol) had no consistent antagonistic effect or actually enhanced one or more of the behavioral effects of PCP. Some neuroleptics slightly reduced PCP locomotion or stereotypies at high doses, but these effects were probably a non-specific consequence of the synergistic ataxia-producing properties of these drugs. In a second set of experiments, atropine sulfate pretreatment increased PCP-induced locomotor activity and stereotyped behaviors but had no effect on ataxia; pretreatment with physostigmine produced opposite effects. Combined pretreatment with haloperidol and atropine sulfate significantly reduced only haloperidol antagonism of PCP-induced ataxia, thus suggesting that non-dopoaminergic effects of neuroleptics may interfere with their ability to antagonize PCP.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6119221     DOI: 10.1016/0014-2999(81)90007-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Phencyclidine-induced increases in striatal neuron firing in behaving rats: reversal by haloperidol and clozapine.

Authors:  I M White; G S Flory; K C Hooper; J Speciale; D A Banks; G V Rebec
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Effects of phencyclidine, haloperidol, and naloxone on fixed-interval performance in rats.

Authors:  G C Wagner; D B Masters; A Tomie
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 3.  Glutamate and dopamine components in schizophrenia.

Authors:  Philip Seeman
Journal:  J Psychiatry Neurosci       Date:  2009-03       Impact factor: 6.186

4.  Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens: comparisons to other psychomotor stimulants.

Authors:  E D French; G Vantini
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  Phencyclidine-induced disruption of an aversely motivated two-choice successive discrimination in the rat.

Authors:  E Ericson; S Ahlenius
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  A possible role of AA2 excitatory amino acid receptors in the expression of stimulant drug effects.

Authors:  W J Freed; H E Cannon-Spoor
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Blockade of NMDA receptors in the prefrontal cortex increases dopamine and acetylcholine release in the nucleus accumbens and motor activity.

Authors:  Alberto Del Arco; Gregorio Segovia; Francisco Mora
Journal:  Psychopharmacology (Berl)       Date:  2008-08-28       Impact factor: 4.530

8.  Circling behavior induced by phencyclidine in mice and its inhibition by naloxone.

Authors:  Y Eshel; A M Korczyn
Journal:  Experientia       Date:  1985-01-15

9.  Involvement of the Striatal Medium Spiny Neurons of the Direct Pathway in the Motor Stimulant Effects of Phencyclidine.

Authors:  Alessandra Bonito-Oliva; Caitlin DuPont; Nather Madjid; Sven Ove Ögren; Gilberto Fisone
Journal:  Int J Neuropsychopharmacol       Date:  2015-12-09       Impact factor: 5.176

10.  Acute NMDA receptor antagonism disrupts synchronization of action potential firing in rat prefrontal cortex.

Authors:  Leonardo A Molina; Ivan Skelin; Aaron J Gruber
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.